What do systematic reviews say?

Tinzaparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tinzaparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tinzaparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tinzaparin vs placebo

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 253 participants
  Very low

Tinzaparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tinzaparin vs placebo

Tinzaparin showed no clear difference in adverse events associated with the use of anticoagulants (e.g.… compared with placebo (low certainty).

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  RR 4.96 [0.24, 102.31]
  1 study · 253 participants
  Low

Intervention not reported

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 200 participants
  Low

Intervention not reported

The intervention showed no clear difference in catheter‐related thrombosis at any time during catheter stay (moderate certainty).

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  RR 0.34 [0.01, 7.68]
  2 studies · 287 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in occlusion of catheter within one week of catheter insertion (low certainty).

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  RR 0.06 [0, 1.07]
  1 study · 200 participants
  Low

Intervention not reported

The intervention may leads to lower catheter‐related blood stream infection and CVC‐related colonization (low certainty).

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  RR 0.06 [0.01, 0.41]
  1 study · 200 participants
  Low

Intervention not reported

The intervention showed no clear difference in side effects: Thrombocytopenia after catheter insertion (low certainty).

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  RR 0.73 [0.38, 1.39]
  2 studies · 287 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes live birth rate per woman (very low certainty).

• Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
  OR 1.77 [1.07, 2.9]
  3 studies · 386 participants
  Very low

Intervention not reported

The intervention may leads to higher clinical pregnancy rate per woman (low certainty).

• Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
  OR 1.61 [1.03, 2.53]
  3 studies · 386 participants
  Low

Intervention not reported

• Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
  no estimate extracted
  5 participants
  GRADE not reported

Intervention not reported

It is very uncertain whether the intervention changes live birth rate per woman (very low certainty).

• Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
  OR 1.85 [0.8, 4.24]
  3 studies · 386 participants
  Very low

Intervention not reported

The intervention showed no clear difference in clinical pregnancy rate per woman (low certainty).

• Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
  OR 1.66 [0.94, 2.9]
  3 studies · 386 participants
  Low

Intervention not reported

• Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
  no estimate extracted
  5 participants
  GRADE not reported

Direct thrombin inhibitors vs vitamin K antagonist (VKA)

Direct thrombin inhibitors showed no clear difference in major VTE events in TKR combined doses bilateral ascending venography compared with vitamin K antagonists (low certainty).

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
  OR 0.85 [0.63, 1.15]
  3 studies · 4327 participants
  Low

Direct thrombin inhibitors vs vitamin K antagonist (VKA)

Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
  OR 1.62 [0.57, 4.58]
  3 studies · 5243 participants
  Low

Direct thrombin inhibitors vs vitamin K antagonist (VKA)

Direct thrombin inhibitors showed no clear difference in total Bleeding events in TKR combined doses compared with vitamin K antagonists (low certainty).

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
  OR 1.26 [0.97, 1.62]
  3 studies · 5259 participants
  Low